The impact of COVID-19 pandemic on aortic valve surgical service: a single centre experience.


Journal

BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539

Informations de publication

Date de publication:
14 09 2021
Historique:
received: 17 03 2021
accepted: 07 09 2021
entrez: 15 9 2021
pubmed: 16 9 2021
medline: 23 9 2021
Statut: epublish

Résumé

The coronavirus-disease 2019 (COVID-19) pandemic imposed an unprecedented burden on the provision of cardiac surgical services. The reallocation of workforce and resources necessitated the postponement of elective operations in this cohort of high-risk patients. We investigated the impact of this outbreak on the aortic valve surgery activity at a single two-site centre in the United Kingdom. Data were extracted from the local surgical database, including the demographics, clinical characteristics, and outcomes of patients operated on from March 2020 to May 2020 with only one of the two sites resuming operative activity and compared with the respective 2019 period. A similar comparison was conducted with the period between June 2020 and August 2020, when operative activity was restored at both institutional sites. The experience of centres world-wide was invoked to assess the efficiency of our services. There was an initial 38.2% reduction in the total number of operations with a 70% reduction in elective cases, compared with a 159% increase in urgent and emergency operations. The attendant surgical risk was significantly higher [median Euroscore II was 2.7 [1.9-5.2] in 2020 versus 2.1 [0.9-3.7] in 2019 (p = 0.005)] but neither 30-day survival nor freedom from major post-operative complications (re-sternotomy for bleeding/tamponade, transient ischemic attack/stroke, renal replacement therapy) was compromised (p > 0.05 for all comparisons). Recommencement of activity at both institutional sites conferred a surgical volume within 17% of the pre-COVID-19 era. Our institution managed to offer a considerable volume of aortic valve surgical activity over the first COVID-19 outbreak to a cohort of higher-risk patients, without compromising post-operative outcomes. A backlog of elective cases is expected to develop, the accommodation of which after surgical activity normalisation will be crucial to monitor.

Sections du résumé

BACKGROUND
The coronavirus-disease 2019 (COVID-19) pandemic imposed an unprecedented burden on the provision of cardiac surgical services. The reallocation of workforce and resources necessitated the postponement of elective operations in this cohort of high-risk patients. We investigated the impact of this outbreak on the aortic valve surgery activity at a single two-site centre in the United Kingdom.
METHODS
Data were extracted from the local surgical database, including the demographics, clinical characteristics, and outcomes of patients operated on from March 2020 to May 2020 with only one of the two sites resuming operative activity and compared with the respective 2019 period. A similar comparison was conducted with the period between June 2020 and August 2020, when operative activity was restored at both institutional sites. The experience of centres world-wide was invoked to assess the efficiency of our services.
RESULTS
There was an initial 38.2% reduction in the total number of operations with a 70% reduction in elective cases, compared with a 159% increase in urgent and emergency operations. The attendant surgical risk was significantly higher [median Euroscore II was 2.7 [1.9-5.2] in 2020 versus 2.1 [0.9-3.7] in 2019 (p = 0.005)] but neither 30-day survival nor freedom from major post-operative complications (re-sternotomy for bleeding/tamponade, transient ischemic attack/stroke, renal replacement therapy) was compromised (p > 0.05 for all comparisons). Recommencement of activity at both institutional sites conferred a surgical volume within 17% of the pre-COVID-19 era.
CONCLUSIONS
Our institution managed to offer a considerable volume of aortic valve surgical activity over the first COVID-19 outbreak to a cohort of higher-risk patients, without compromising post-operative outcomes. A backlog of elective cases is expected to develop, the accommodation of which after surgical activity normalisation will be crucial to monitor.

Identifiants

pubmed: 34521355
doi: 10.1186/s12872-021-02253-6
pii: 10.1186/s12872-021-02253-6
pmc: PMC8438903
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

434

Informations de copyright

© 2021. The Author(s).

Références

Curr Probl Cardiol. 2020 Aug;45(8):100618
pubmed: 32439197
Eur J Cardiothorac Surg. 2020 Jun 1;57(6):1025-1028
pubmed: 32301984
Int J Surg. 2020 Jul;79:168-179
pubmed: 32407799
Hellenic J Cardiol. 2021 May-Jun;62(3):231-233
pubmed: 32679176
J Card Surg. 2020 Jul;35(7):1563-1569
pubmed: 32598501
J Card Surg. 2020 Aug;35(8):1988-2008
pubmed: 32652713
J Card Surg. 2020 Jun;35(6):1295-1297
pubmed: 32419218
J Card Surg. 2021 May;36(5):1649-1658
pubmed: 32981073
J Am Heart Assoc. 2020 Jul 7;9(13):e017042
pubmed: 32418460
Semin Cardiothorac Vasc Anesth. 2021 Jun;25(2):151-155
pubmed: 33988047
J Card Surg. 2020 Jun;35(6):1287-1294
pubmed: 32369872
J Cardiothorac Surg. 2021 Mar 22;16(1):43
pubmed: 33752706
Heart. 2020 Nov;106(21):1624-1626
pubmed: 32788177
Circulation. 2020 Jul 21;142(3):300-302
pubmed: 32392425
Eur Heart J Qual Care Clin Outcomes. 2021 May 3;7(3):247-256
pubmed: 33079204
Int J Surg. 2020 Jul;79:233-248
pubmed: 32413502
Heart. 1999 Jun;81(6):586-92
pubmed: 10336915

Auteurs

Dimitrios Vlastos (D)

Royal Brompton and Harefield NHS Foundation Trust, London, UK. dimitrisbvr@hotmail.com.

Ishaansinh Chauhan (I)

Royal Brompton and Harefield NHS Foundation Trust, London, UK.

Kwabena Mensah (K)

Royal Brompton and Harefield NHS Foundation Trust, London, UK.

Maria Cannoletta (M)

Royal Brompton and Harefield NHS Foundation Trust, London, UK.

Athanasios Asonitis (A)

Royal Brompton and Harefield NHS Foundation Trust, London, UK.

Ahmed Elfadil (A)

Royal Brompton and Harefield NHS Foundation Trust, London, UK.

Mario Petrou (M)

Royal Brompton and Harefield NHS Foundation Trust, London, UK.

Anthony De Souza (A)

Royal Brompton and Harefield NHS Foundation Trust, London, UK.

Cesare Quarto (C)

Royal Brompton and Harefield NHS Foundation Trust, London, UK.

Sunil K Bhudia (SK)

Royal Brompton and Harefield NHS Foundation Trust, London, UK.

Ulrich Rosendahl (U)

Royal Brompton and Harefield NHS Foundation Trust, London, UK.

John Pepper (J)

Royal Brompton and Harefield NHS Foundation Trust, London, UK.

George Asimakopoulos (G)

Royal Brompton and Harefield NHS Foundation Trust, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH